MYCN and neuroblastoma: Of particular note, the Felix neuroblastoma PDX, which was established post-mortem from the blood of a patient who died of ALKF1245C MYCN-non-amplified high-risk neuroblastoma, has been part of several publications to highlight the potential of synergy between ALK inhibition and chemotherapy [76], the resistance to ALK inhibition mediated by Pim1 [77], and the study of novel ALK-antibody conjugates [78].